← All trials
NCT04918147
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 13, 2021
- Primary completion
- Jun 30, 2024
- Completion date
- Nov 30, 2024
- First posted
- Jun 8, 2021
- Last posted
- Oct 15, 2021
- Enrollment
- 75
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)Collaborator
- Harvard UniversityStudy chair
- Rho, Inc.Collaborator
- Harvard UniversityOfficial
- Bristol-Myers SquibbCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.